Thrivent Financial For Lutherans Supernus Pharmaceuticals, Inc. Transaction History

Thrivent Financial For Lutherans

$45.7 Billion
Q2 2025

A detailed history of Thrivent Financial For Lutherans transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Thrivent Financial For Lutherans holds 41,170 shares of SUPN stock, worth $2.05 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

41,170

Previous 40,559 1.51%

Holding current value

$2.05 Million

Previous $1.33 Million 2.26%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 26, 2025	BUY	$30.29 - $33.43 $18,507 - $20,425	611 Added 1.51%	41,170 $1.3 Million
Q1 2025 Aug 26, 2025	BUY	$31.17 - $40.0 $1.26 Million - $1.62 Million	40,559 New	40,559 $1.33 Million
Q4 2024 Feb 10, 2025	SELL	$31.89 - $37.83 $18,846 - $22,357	-591 Reduced 1.37%	42,682 $1.54 Million
Q3 2024 Nov 07, 2024	SELL	$25.77 - $35.16 $60,894 - $83,083	-2,363 Reduced 5.18%	43,273 $1.35 Million
Q2 2024 Aug 13, 2024	SELL	$25.99 - $33.85 $45,716 - $59,542	-1,759 Reduced 3.71%	45,636 $1.22 Million
Q1 2024 May 14, 2024	SELL	$27.11 - $35.17 $34,890 - $45,263	-1,287 Reduced 2.64%	47,395 $1.62 Million
Q4 2023 Feb 14, 2024	SELL	$22.72 - $29.68 $28,627 - $37,396	-1,260 Reduced 2.52%	48,682 $1.41 Million
Q3 2023 Nov 14, 2023	SELL	$27.57 - $32.91 $59,854 - $71,447	-2,171 Reduced 4.17%	49,942 $1.38 Million
Q2 2023 Aug 14, 2023	SELL	$29.91 - $38.73 $43,638 - $56,507	-1,459 Reduced 2.72%	52,113 $1.57 Million
Q1 2023 May 17, 2023	SELL	$34.93 - $42.03 $65,598 - $78,932	-1,878 Reduced 3.39%	53,572 $1.94 Million
Q4 2022 Feb 08, 2023	BUY	$31.09 - $37.88 $4,694 - $5,719	151 Added 0.27%	55,450 $1.98 Million
Q3 2022 Nov 14, 2022	BUY	$28.79 - $35.41 $81,302 - $99,997	2,824 Added 5.38%	55,299 $1.87 Million
Q2 2022 Aug 16, 2022	BUY	$25.33 - $34.25 $232,580 - $314,483	9,182 Added 21.21%	52,475 $1.52 Million
Q1 2022 May 13, 2022	BUY	$28.51 - $32.9 $399 - $460	14 Added 0.03%	43,293 $1.4 Million
Q4 2021 Feb 16, 2022	BUY	$26.37 - $34.22 $8,464 - $10,984	321 Added 0.75%	43,279 $1.26 Million
Q3 2021 Nov 15, 2021	SELL	$23.54 - $31.39 $9,062 - $12,085	-385 Reduced 0.89%	42,958 $1.15 Million
Q2 2021 Aug 19, 2021	SELL	$26.72 - $33.19 $3,500 - $4,347	-131 Reduced 0.3%	43,343 $1.34 Million
Q1 2021 May 17, 2021	SELL	$24.15 - $31.45 $3,260 - $4,245	-135 Reduced 0.31%	43,474 $1.14 Million
Q4 2020 Feb 16, 2021	SELL	$17.7 - $25.81 $1,044 - $1,522	-59 Reduced 0.14%	43,609 $1.1 Million
Q3 2020 Nov 10, 2020	SELL	$20.2 - $25.05 $6,080 - $7,540	-301 Reduced 0.68%	43,668 $910,000
Q1 2020 May 15, 2020	BUY	$14.45 - $24.69 $31,717 - $54,194	2,195 Added 5.25%	43,969 $791,000
Q4 2019 Feb 13, 2020	BUY	$19.93 - $29.13 $1,993 - $2,913	100 Added 0.24%	41,774 $991,000
Q3 2019 Nov 14, 2019	BUY	$25.47 - $33.37 $15,995 - $20,956	628 Added 1.53%	41,674 $1.15 Million
Q2 2019 Aug 13, 2019	BUY	$29.96 - $38.87 $33,195 - $43,067	1,108 Added 2.77%	41,046 $1.36 Million
Q1 2019 May 14, 2019	BUY	$32.77 - $41.99 $93,525 - $119,839	2,854 Added 7.7%	39,938 $1.4 Million
Q4 2018 Feb 15, 2019	BUY	$30.84 - $49.51 $25,134 - $40,350	815 Added 2.25%	37,084 $1.23 Million
Q3 2018 Nov 15, 2018	BUY	$42.7 - $56.55 $31,469 - $41,677	737 Added 2.07%	36,269 $1.83 Million
Q2 2018 Aug 14, 2018	BUY	$44.1 - $59.85 $37,926 - $51,471	860 Added 2.48%	35,532 $2.13 Million
Q1 2018 May 08, 2018	BUY	$37.15 - $46.9 $110,224 - $139,152	2,967 Added 9.36%	34,672 $1.59 Million
Q4 2017 Feb 14, 2018	BUY	$36.4 - $42.6 $22,750 - $26,625	625 Added 2.01%	31,705 $1.26 Million
Q3 2017 Nov 14, 2017	BUY	$36.75 - $49.65 $1.14 Million - $1.54 Million	31,080	31,080 $1.24 Million

Others Institutions Holding SUPN

# of Institutions

313

Shares Held

61.5M

Call Options Held

18.4K

Put Options Held

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.66B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

News

Stay updated on Thrivent Financial For Lutherans with notifications on news.

Account

Thrivent Financial For Lutherans Supernus Pharmaceuticals, Inc. Transaction History